Xeris Pharmaceuticals Receives U.S. Patent For Its Novel, Stable Non-Aqueous Glucagon Formulations
4/16/2014 9:19:55 AM
Austin, Texas, April 16, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that is has been granted U.S. Patent No. 8,697,644, "Stable Formulations for Parenteral Injection of Peptide Drugs". The new formulation technology will enable peptides that are typically given as aqueous injections to be reformulated into biocompatible, concentrated, non-aqueous solutions. Different from their predecessors, these formulations can be directly injected without reconstitution, saving time during medical emergencies related to Type 1 diabetes among other diseases. This is the second patent issued that supports Xeris' novel,non-aqueous drug delivery technology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by